JMEE - ETF AI Analysis

Top Page

JPMorgan Market Expansion Enhanced Equity ETF (JMEE)

Rating:68Neutral

Price Target:―

JMEE’s rating suggests it is a solid but not top-tier ETF, supported by strong holdings like United Therapeutics, Woodward, and RBC Bearings, which all show robust financial performance, positive earnings calls, and generally supportive technical trends. However, some positions such as Coherent, Lumentum, nVent Electric, and Casey’s General Stores face issues like high valuations, weaker technical momentum, or cash flow concerns, which weigh on the overall assessment. A key risk factor is that several holdings share similar valuation and technical risks, meaning the fund is somewhat exposed to overvaluation and periods of short-term price weakness across multiple names.

Positive Factors

Solid Recent Performance

The ETF has shown strong gains over the past three and twelve months, indicating positive recent momentum.

Broad Sector Diversification

Holdings are spread across many sectors such as industrials, financials, technology, and consumer-related areas, which helps reduce the impact of weakness in any single industry.

Growing Asset Base with Moderate Fees

The fund manages a sizable pool of assets with a relatively low expense ratio for an actively managed strategy, suggesting investor confidence while keeping ongoing costs reasonable.

Negative Factors

Heavy U.S. Concentration

With nearly all assets invested in U.S. companies, the ETF offers very limited geographic diversification and is highly tied to the U.S. market.

Small Individual Position Sizes

Top holdings each make up only a small slice of the portfolio, which can dilute the impact of its strongest-performing stocks on overall returns.

Mixed Performance Among Top Holdings

While several leading positions have delivered strong gains, a few key holdings have shown weaker or negative performance, which can drag on the fund’s overall results.

JMEE vs. SPDR S&P 500 ETF (SPY)

AUM2.24B

RegionNorth America

Expense Ratio0.24%

Beta0.95

IssuerJPMorgan

Inception DateMay 06, 2022

Dividend Yield1.1%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume162,090

30 Day Avg. Volume120,428

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

80.04

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering658

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

JMEE Summary

JMEE is the JPMorgan Market Expansion Enhanced Equity ETF, focused on the “extended market,” mainly mid-size and smaller U.S. companies rather than the big household-name giants. It does not track a set index, but instead uses JPMorgan’s research to pick a wide mix of stocks across many sectors, including industrials, financials, and technology. Well-known holdings include companies like Ciena and United Therapeutics. Someone might invest in JMEE to seek extra growth and diversification beyond large-cap funds. A key risk is that mid- and small-cap stocks can be more volatile and can go up and down more than the overall market.

How much will it cost me?The expense ratio for the JPMorgan Market Expansion Enhanced Equity ETF (JMEE) is 0.24%, which means you’ll pay $2.40 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it uses JPMorgan's strategies to enhance returns while keeping costs relatively low.

What would affect this ETF?JMEE's focus on U.S. mid-cap and small-cap companies could benefit from economic growth and innovation in sectors like technology and industrials, which are key areas of exposure for the ETF. However, it may face challenges during periods of economic uncertainty or rising interest rates, which can negatively impact smaller companies and sectors like real estate and consumer cyclical. Regulatory changes or shifts in market sentiment could also influence the performance of its top holdings.

JMEE Top 10 Holdings

JMEE leans heavily into U.S. mid- and small-cap industrial and tech names, and that’s where much of the action is. Woodward, MasTec, and nVent Electric have been quietly powering the fund, with steady-to-rising momentum that reflects solid earnings and growth stories. Lumentum and Coherent add a more volatile tech edge, recently climbing but with valuations that can make the ride bumpy. On the flip side, United Therapeutics has been more of a flat tire than an engine lately, slightly dragging performance in an otherwise broadly constructive, domestically focused portfolio.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
	―	2.94%	$66.99M	―	―	―
LITE	Lumentum Holdings	0.92%	$20.82M	$43.99B	921.88%	61 Neutral
COHR	Coherent Corp	0.90%	$20.37M	$45.23B	286.65%	66 Neutral
UTHR	United Therapeutics	0.76%	$17.33M	$23.35B	74.47%	79 Outperform
CW	Curtiss-Wright	0.74%	$16.83M	$25.08B	116.55%	74 Outperform
WWD	Woodward	0.74%	$16.74M	$21.57B	104.56%	79 Outperform
MTZ	MasTec	0.67%	$15.18M	$23.43B	154.83%	74 Outperform
NVT	nVent Electric	0.60%	$13.62M	$17.45B	99.06%	76 Outperform
CASY	Casey's General	0.56%	$12.81M	$24.90B	75.01%	68 Neutral
FTI	TechnipFMC	0.52%	$11.89M	$25.01B	135.92%	80 Outperform

JMEE Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

68.44

Negative

100DMA

66.04

Negative

200DMA

63.23

Positive

Market Momentum

MACD

-0.64

Positive

RSI

32.09

Neutral

STOCH

18.23

Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JMEE, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 69.09, equal to the 50-day MA of 68.44, and equal to the 200-day MA of 63.23, indicating a neutral trend. The MACD of -0.64 indicates Positive momentum. The RSI at 32.09 is Neutral, neither overbought nor oversold. The STOCH value of 18.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JMEE.

JMEE Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
JMEE	―	―	$2.24B	0.24%	68 Neutral
QQQI	―	―	$9.11B	0.68%	75 Outperform
CGUS	―	―	$9.08B	0.33%	72 Outperform
CGMM	―	―	$1.69B	0.51%	67 Neutral
TMSL	―	―	$1.57B	0.55%	69 Neutral
SMIG	―	―	$1.25B	0.60%	73 Outperform

Performance Comparison

JMEE

JPMorgan Market Expansion Enhanced Equity ETF

65.81

9.81

17.52%

QQQI

NEOS Nasdaq 100 High Income ETF

―

CGUS

Capital Group Core Equity ETF

―

CGMM

Capital Group U.S. Small and Mid Cap ETF

―

TMSL

T. Rowe Price Small-Mid Cap ETF

―

SMIG

AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents